# Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease

> **NCT00003414** · PHASE3 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 50 (estimated)

## Conditions studied

- Graft Versus Host Disease
- Lymphoma

## Interventions

- **BIOLOGICAL:** aldesleukin
- **BIOLOGICAL:** recombinant interferon gamma
- **DRUG:** busulfan
- **DRUG:** cyclophosphamide
- **DRUG:** cyclosporine
- **PROCEDURE:** peripheral blood stem cell transplantation
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00003414
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-10
- **Primary completion:** 2004-05
- **Final completion:** 2004-05
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2015-07-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003414

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003414, "Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00003414. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*